Home LiteratureArticle Details
PMID: 19680143 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Journal of neuropathology and experimental neurology ·Vol. 68 ·No. 9 ·2009-09-00 ·Pages 994-1005

Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Hino H, Kosaka K, Emson PC, Wada K, Dawson VL, Dawson TM, Arai H, Iseki E

Abstract

Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common causes of both familial and sporadic forms of Parkinson disease and are also associated with diverse pathological alterations. The mechanisms whereby LRRK2 mutations cause these pathological phenotypes are unknown. We used immunohistochemistry with 3 distinct anti-LRRK2 antibodies to characterize the expression of LRRK2 in the brains of 21 subjects with various neurodegenerative disorders and 7 controls. The immunoreactivity of LRRK2 was localized in a subset of brainstem-type Lewy bodies (LBs) but not in cortical-type LBs, tau-positive inclusions, or TAR-DNA-binding protein-43-positive inclusions. The immunoreactivity of LRRK2 frequently appeared as enlarged granules or vacuoles within neurons of affected brain regions, including the substantia nigra, amygdala, and entorhinal cortex in patients with Parkinson disease or dementia with LBs. The volumes of LRRK2-positive granular structures in neurons of the entorhinal cortex were significantly increased in dementia with LBs brains compared with age-matched control brains (p < 0.05). Double immunolabeling demonstrated that these LRRK2-positive granular structures frequently colocalized with the late-endosomal marker Rab7B and occasionally with the lysosomal marker, the lysosomal-associated membrane protein 2. These results suggest that LRRK2 normally localizes to the endosomal-lysosomal compartment within morphologically altered neurons in neurodegenerative diseases, particularly in the brains of patients with LB diseases.

MeSH Terms
Aged Alzheimer Disease/metabolism,pathology Brain/metabolism,pathology Dementia/metabolism,pathology Endosomes/metabolism,pathology Female Fluorescent Antibody Technique Humans Immunohistochemistry Inclusion Bodies/metabolism,pathology Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Lewy Body Disease/metabolism,pathology Lysosomes/metabolism,pathology Male Middle Aged Neurons/metabolism,pathology Parkinson Disease/metabolism,pathology Pick Disease of the Brain/metabolism,pathology Protein Serine-Threonine Kinases/metabolism Supranuclear Palsy, Progressive/metabolism,pathology
Chemicals
LRRK2 protein, human Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Protein Serine-Threonine Kinases
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Higashi Shinji
PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Koto-ku, Tokyo, Japan. higashis@ncnp.go.jp
Moore Darren J
Yamamoto Ryoko
Minegishi Michiko
Sato Kiyoshi
Togo Takashi
Katsuse Omi
Uchikado Hirotake
Furukawa Yoshiko
Hino Hiroaki
Kosaka Kenji
Emson Piers C
Wada Keiji
Dawson Valina L
Dawson Ted M
Arai Heii
Iseki Eizo
References (59)
59 references, click to expand
  1. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    Science. 2003 Jan 10;299(5604):256-9 PMID: 12446870
  2. LRRK2 expression linked to dopamine-innervated areas.
    Ann Neurol. 2006 Apr;59(4):714-9 PMID: 16532471
  3. Localization of LRRK2 to membranous and vesicular structures in mammalian brain.
    Ann Neurol. 2006 Nov;60(5):557-69 PMID: 17120249
  4. The familial Parkinsonism gene LRRK2 regulates neurite process morphology.
    Neuron. 2006 Nov 22;52(4):587-93 PMID: 17114044
  5. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.
    Nat Genet. 2006 Oct;38(10):1184-91 PMID: 16964263
  6. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology.
    Am J Pathol. 2002 Nov;161(5):1869-79 PMID: 12414533
  7. Biochemical and pathological characterization of Lrrk2.
    Ann Neurol. 2006 Feb;59(2):315-22 PMID: 16437584
  8. The cellular pathology of Parkinson's disease.
    Neuropathology. 2001 Dec;21(4):315-22 PMID: 11837539
  9. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
    Nature. 1998 Apr 9;392(6676):605-8 PMID: 9560156
  10. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
    Neuroscience. 2007 Jul 29;147(4):1047-58 PMID: 17611037
  11. Dynamic and redundant regulation of LRRK2 and LRRK1 expression.
    BMC Neurosci. 2007 Nov 28;8:102 PMID: 18045479
  12. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.
    Neuroscience. 2006;139(3):791-4 PMID: 16504409
  13. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
    Science. 2004 Aug 27;305(5688):1292-5 PMID: 15333840
  14. Autophagy and neurodegeneration: when the cleaning crew goes on strike.
    Lancet Neurol. 2007 Apr;6(4):352-61 PMID: 17362839
  15. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  16. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
    Ann Neurol. 2000 Apr;47(4):521-3 PMID: 10762166
  17. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
    Brain Res. 2007 Dec 12;1184:284-94 PMID: 17963732
  18. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Lancet Neurol. 2008 Jul;7(7):591-4 PMID: 18539535
  19. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.
    J Neurochem. 2007 Jan;100(2):368-81 PMID: 17101029
  20. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Brain Res. 2007 Jun 25;1155:208-19 PMID: 17512502
  21. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
    Neurology. 2006 Oct 24;67(8):1506-8 PMID: 17060589
  22. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease.
    Acta Neuropathol. 2004 Aug;108(2):121-8 PMID: 15235805
  23. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Mov Disord. 2007 Jan 15;22(2):275-8 PMID: 17149743
  24. Diagnostic criteria for Parkinson disease.
    Arch Neurol. 1999 Jan;56(1):33-9 PMID: 9923759
  25. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study.
    J Neuropathol Exp Neurol. 2005 Feb;64(2):113-22 PMID: 15751225
  26. A common LRRK2 mutation in idiopathic Parkinson's disease.
    Lancet. 2005 Jan 29-Feb 4;365(9457):415-6 PMID: 15680457
  27. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.
    Acta Neuropathol. 2007 May;113(5):601-6 PMID: 17151837
  28. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.
    Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2 PMID: 9330978
  29. Kinase activity of mutant LRRK2 mediates neuronal toxicity.
    Nat Neurosci. 2006 Oct;9(10):1231-3 PMID: 16980962
  30. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
    Neuron. 2004 Nov 18;44(4):595-600 PMID: 15541308
  31. Loss of autophagy in the central nervous system causes neurodegeneration in mice.
    Nature. 2006 Jun 15;441(7095):880-4 PMID: 16625205
  32. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    J Neurochem. 2008 May;105(3):1048-56 PMID: 18182054
  33. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Neuron. 2004 Nov 18;44(4):601-7 PMID: 15541309
  34. Accumulation of phosphorylated alpha-synuclein in aging human brain.
    J Neuropathol Exp Neurol. 2003 Jun;62(6):644-54 PMID: 12834109
  35. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.
    Nature. 2006 Jun 15;441(7095):885-9 PMID: 16625204
  36. LRRK2 in Parkinson's disease and dementia with Lewy bodies.
    Mol Neurodegener. 2006 Nov 30;1:17 PMID: 17137507
  37. LRRK2 protein is a component of Lewy bodies.
    Ann Neurol. 2006 Nov;60(5):617-8; author reply 618-9 PMID: 16847950
  38. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.
    Acta Neuropathol. 2006 Oct;112(4):389-404 PMID: 16906426
  39. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Hum Mol Genet. 2006 Jan 15;15(2):223-32 PMID: 16321986
  40. LRRK2 expression in normal and pathologic human brain and in human cell lines.
    J Neuropathol Exp Neurol. 2006 Oct;65(10):953-63 PMID: 17021400
  41. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.
    Neurology. 2004 May 11;62(9):1619-22 PMID: 15136696
  42. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.
    Am J Hum Genet. 2005 Apr;76(4):672-80 PMID: 15726496
  43. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
    Neurology. 2005 Dec 27;65(12):1863-72 PMID: 16237129
  44. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis.
    Neuron. 2006 Oct 5;52(1):15-31 PMID: 17015224
  45. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.
    J Neurosci. 2004 Feb 25;24(8):1888-96 PMID: 14985429
  46. Lrrk2 and Lewy body disease.
    Ann Neurol. 2006 Feb;59(2):388-93 PMID: 16437559
  47. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    Hum Mol Genet. 2007 Jan 15;16(2):223-32 PMID: 17200152
  48. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Lancet Neurol. 2008 Jul;7(7):583-90 PMID: 18539534
  49. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
    Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7 PMID: 16269541
  50. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Neurodegener Dis. 2008;5(3-4):222-4 PMID: 18322396
  51. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Histol Histopathol. 1997 Jan;12(1):25-31 PMID: 9046040
  52. Hereditary early-onset Parkinson's disease caused by mutations in PINK1.
    Science. 2004 May 21;304(5674):1158-60 PMID: 15087508
  53. Distribution of PINK1 and LRRK2 in rat and mouse brain.
    J Neurochem. 2006 Aug;98(3):951-61 PMID: 16771836
  54. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
    Neurobiol Dis. 2006 Aug;23(2):329-41 PMID: 16750377
  55. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8 PMID: 18602856
  56. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy.
    Eur Neurol. 1997;38 Suppl 1:39-43 PMID: 9276200
  57. LRRK2 regulates synaptic vesicle endocytosis.
    Exp Cell Res. 2008 Jun 10;314(10):2055-65 PMID: 18445495
  58. Alpha-Synuclein is degraded by both autophagy and the proteasome.
    J Biol Chem. 2003 Jul 4;278(27):25009-13 PMID: 12719433
  59. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.
    J Neurosci. 1997 Aug 15;17(16):6142-51 PMID: 9236226
Article Info
Journal
Journal of neuropathology and experimental neurology
Abbr.
J Neuropathol Exp Neurol
ISSN
0022-3069
Published
2009-09-00
Pages
994-1005
Language
English
Region
England
NLM ID
2985192R
PMCID
PMC2768772
Subset
IM
Grants
NINDS NIH HHS · P50 NS038377 · United States
NINDS NIH HHS · P50 NS038377-10 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com